Accuray, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US0043971052
USD
1.02
-0.01 (-0.97%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Accuray, Inc. stock-summary
stock-summary
Accuray, Inc.
Pharmaceuticals & Biotechnology
Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy. The CyberKnife Systems are robotic systems that are used to treat various types of cancer and tumors throughout the body. The CyberKnife Systems track, detect and correct for tumor and patient movement in real-time during the procedure. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.
Company Coordinates stock-summary
Company Details
1310 Chesapeake Ter , SUNNYVALE CA : 94089-1100
stock-summary
Tel: 1 408 71646001 602 7177804
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 45 Schemes (20.73%)

Foreign Institutions

Held by 37 Foreign Institutions (4.62%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Louis Lavigne
Independent Chairperson of the Board
Mr. Joshua Levine
President, Chief Executive Officer, Director
Ms. Elizabeth Davila
Independent Director
Mr. James Hindman
Independent Director
Ms. Beverly Huss
Independent Director
Ms. Anne Le Grand
Independent Director
Mr. Richard Pettingill
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
128 Million
(Quarterly Results - Jun 2025)
Net Profit:
1 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 175 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

1.06

stock-summary
Return on Equity

-2.63%

stock-summary
Price to Book

2.15